TrialGynecologic oncology2022

Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma.

Ainhoa Madariaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.